NAD+ and Sermorelin Together: What Is Known
NAD+ and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Coenzyme (injectable, IV or nasal)CompoundedNAD+Coenzyme sold as an injectable wellness product; a systematic review concluded clinical effectiveness for anti-aging or wellness outcomes remains inconclusive.[11]
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[12]Growth hormoneInteraction notes
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component
Side by side
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | NAD+ | Sermorelin |
|---|---|---|
| Class | Coenzyme (injectable, IV or nasal) | GHRH analog |
| Also called | NAD, nicotinamide adenine dinucleotide | — |
| FDA status | Compounded | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | No published half-life foundPubMed search, 2 Oct 2026 |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | [n] | 4 human (1 randomized or controlled) of 7 summarised |
| Typical study doses | [dose range] |
|
Related tools
NAD+ vs Sermorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
What people search
- nad and sermorelin110/mo
- nad sermorelin70/mo
- sermorelin and nad50/mo
- nad and sermorelin together40/mo
- sermorelin nad30/mo
- sermorelin with nad10/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
- 12Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
Found an error? Report a correction.